A jumping-gene startup raises $56M to insert genes without viruses

Typewriter Therapeutics came out of stealth on 2 September 2026 with a $56 million Series A led by AN Venture Partners and RA Capital Management, joined by ANRI, Gemseki and the SBI US Gateway Fund. The company works out of Cambridge, Massachusetts and Tokyo, and its science descends from work by Haruhiko Fujiwara, professor emeritus at the University of Tokyo, on the R2 retrotransposon — a jumping gene that copies itself into one fixed spot in the genome.

The mechanism Typewriter is commercialising is target-primed reverse transcription. Two RNAs travel in a lipid nanoparticle: one encodes the R2 protein, the other carries the therapeutic gene. They assemble into an active complex that inserts the gene at the target site. Nothing viral is involved, and that is the pitch — the company says delivering RNA in a lipid nanoparticle rather than an AAV vector is what makes a genetic medicine re-dosable. Its first targets are in vivo CAR-T therapy and genetic liver disease.

This is early. First studies in non-human primates are planned for late 2026, so no animal efficacy data are in the public record yet, let alone human data. What the round buys is a bet on the delivery problem rather than the editing problem: gene-insertion programmes tend to be limited less by whether they can write into the genome than by how many times a patient can safely receive the vehicle that carries the machinery.